MedPath

Clinical Of Plain Balloon Dilatation Combined Stent Versus Endovascular Debulking Combined Drug-coated Balloon to Treat Arteriosclerosis Occlusive Disease of Lower Extremity

Not Applicable
Recruiting
Conditions
Ischemia
Atherosclerosis
Interventions
Device: balloon and Stent
Device: endovascular debulking and DCB
Registration Number
NCT05158257
Lead Sponsor
Xuanwu Hospital, Beijing
Brief Summary

This is a Prospective randomized controlled study to evaluate the difference of safety,effectiveness between endovascular debulking combined drug-coated balloon and balloon dilatation combined stent angioplasty in treatment of femoral-popliteal artery lesions.

Detailed Description

Prospective randomized controlled study to evaluate the difference of safety,effectiveness between endovascular debulking combined drug-coated balloon and balloon dilatation combined stent angioplasty in treatment of femoral-popliteal artery lesions. Patients with femoral-popliteal artery lesions in our department were randomly assigned to the endovascular debulking combined drug-coated balloon group and balloon dilatation combined with stent angioplasty group. Compare the ischemic improvement rate (limb salvage rate, postoperative patency rate) and the complications rate of two different treatments. At the same time, the peri-operative related factors that may affect the end point events, such as preoperative baseline data, lesion characteristics, imaging features, stent fracture, and end point observation indexes were analyzed by regression analysis.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
144
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Intervention: balloon and Stentsballoon and Stentplain balloon and Stents group
Intervention: debulking and drug coated balloonendovascular debulking and DCBdebulking and drug coated balloon group
Primary Outcome Measures
NameTimeMethod
12-month Primary Patency Rate12 months

systolic velocity ratio \>2.4 as measured by Duplex ultrasound.

Secondary Outcome Measures
NameTimeMethod
Major Adverse Events at 12-month Post Procedure12 months

Major adverse events included death, index limb ischemia, index limb amputation, clinically driven target lesion revascularization , and significant embolic events, which were defined as causing end-organ damage.

12-month Limb Salvage Rate12 months

Limb Salvage is defined as the freedom from secondary major amputation

Technical success rate1 day

Technical success was defined as residual stenosis less than 30% by final

freedom from clinically-driven TLR rate12 months

it is defined as the freedom from clinically-driven target lesion revascularization

Trial Locations

Locations (1)

Gu Yong Quan

🇨🇳

Beijing, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath